Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults)

NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients being treated with non-invasive ventilation (high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical

SPS commentary:

This alert is supported by UK Interim Clinical Commissioning Policies for tocilizumab and sarilumab which describe the criteria for use and exclusion criteria in detail.


Medicines and Healthcare products Regulatory Agency

Resource links:

Interim Clinical Commissioning Policy: Tocilizumab

Interim Clinical Commissioning Policy: Sarilumab